Sugi Predict

Sugi Predict / Compounds / SCHEMBL22119620

SCHEMBL22119620

SCHEMBL22119620

C=CCn1ncc2[nH]c(=O)[nH]c(=O)c21

nearest known ligand 0.38

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ GDA Q9Y2T3 1/20 0.33
▸ TYMP P19971 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ PKM P14618 1/20 0.31
▸ ADORA3 P0DMS8 1/20 0.31
▸ ADORA2B P29275 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.30
▸ POLB P06746 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ CA12 O43570 1/20 0.30
▸ PARP1 P09874 1/20 0.30
▸ CA9 Q16790 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22119225 0.71 EGLN1 (0.36) LMNAPKMALDH1A1POLB
SCHEMBL1096280 0.70 GDA (0.44) GDATYMPLMNAADORA3CYP3A4
SCHEMBL11241808 0.69 GRIA1 (0.47) LMNAPKMADORA3ADORA2BCYP3A4
SCHEMBL843472 0.67 GDA (0.53) GDAADORA3ADORA2BCYP3A4ALDH1A1
SCHEMBL20023764 0.66 GDA (0.34) GDALMNAALDH1A1KDM4E
SCHEMBL874548 0.66 ALDH1A1 (0.39) GDALMNAPKMADORA3ADORA2B
SCHEMBL835443 0.65 DPP4 (0.40) GDALMNAPKMADORA3ADORA2B
SCHEMBL31725530 0.65 SMN1; SMN2 (0.41) LMNACYP3A4ALDH1A1POLBKDM4E
SCHEMBL18440925 0.62 ALDH1A1 (0.36) GDALMNAPKMADORA3ADORA2B
SCHEMBL30861196 0.62 CYP3A4 (0.48) LMNAADORA3ADORA2BCYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12534470-B2 DNA polymerase IIIC inhibitors and use thereof Acurx Pharmaceuticals, Inc. (US) 2026-01-27 — — US disclosed
US-20230250102-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2023-08-10 — — US disclosed
US-20230250102-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2023-08-10 — — US disclosed
US-20230250102-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2023-08-10 — — US disclosed
US-20220112195-A1 DNA Polymerase IIIC Inhibitors and Use Thereof ACURX PHARMACEUTICALS LLC (US) 2022-04-14 — — US disclosed
EP-3897645-A1 DNA POLYMERASE IIIC INHIBITORS AND USE THEREOF Acurx Pharmaceuticals, LLC (US) 2021-10-27 — — EP disclosed
CN-113507929-A DNA polymerase IIIC inhibitor and application thereof 阿科利斯制药有限责任公司 2021-10-15 — — CN disclosed
US-11001592-B2 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2021-05-11 — — US disclosed
US-11001592-B2 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2021-05-11 — — US disclosed
US-10836772-B2 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2020-11-17 — — US disclosed
US-10836772-B2 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2020-11-17 — — US disclosed
US-20200308180-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2020-10-01 — — US disclosed
US-20200308179-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2020-10-01 — — US disclosed
US-20200308179-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2020-10-01 — — US disclosed
US-20200308180-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2020-10-01 — — US disclosed
US-10723741-B1 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2020-07-28 — — US disclosed
US-10723741-B1 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2020-07-28 — — US disclosed
WO-2020132174-A1 DNA POLYMERASE IIIC INHIBITORS AND USE THEREOF ACURX PHARMACEUTICALS, LLC (US) 2020-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112195-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB GDA 200/4885TYMP 28/4885LMNA 1025/4885
US-12534470-B2 DNA polymerase IIIC inhibitors and use thereof POLR1A, POLR2H, POLN GDA 2263/4885TYMP 94/4885LMNA 888/4885
US-20200308180-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB GDA 212/4885TYMP 30/4885LMNA 990/4885
US-20230250102-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB GDA 200/4885TYMP 28/4885LMNA 1025/4885
US-20200308179-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB GDA 212/4885TYMP 30/4885LMNA 990/4885
US-11001592-B2 DNA polymerase IIIC inhibitors and use thereof POLI, POLN, POLB GDA 212/4885TYMP 30/4885LMNA 990/4885
US-10723741-B1 DNA polymerase IIIC inhibitors and use thereof POLI, POLN, POLB GDA 200/4885TYMP 28/4885LMNA 1025/4885
US-10836772-B2 DNA polymerase IIIC inhibitors and use thereof POLI, POLN, POLB GDA 212/4885TYMP 30/4885LMNA 990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.